H.R. 9661: To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Sponsors
2 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Jul. 14, 2026 | Introduced in House |
| Jul. 14, 2026 | Referred to the House Committee on Energy and Commerce. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
Potentially Relevant Congressional Stock Trades
No relevant congressional stock trades found.